Literature DB >> 10098728

Inactivation of the transforming growth factor beta type II receptor in human small cell lung cancer cell lines.

S Hougaard1, P Nørgaard, N Abrahamsen, H L Moses, M Spang-Thomsen, H Skovgaard Poulsen.   

Abstract

Transforming growth factor beta (TGF-beta) exerts a growth inhibitory effect on many cell types through binding to two types of receptors, the type I and II receptors. Resistance to TGF-beta due to lack of type II receptor (RII) has been described in some cancer types including small cell lung cancer (SCLC). The purpose of this study was to examine the cause of absent RII expression in SCLC cell lines. Northern blot analysis showed that RII RNA expression was very weak in 16 of 21 cell lines. To investigate if the absence of RII transcript was due to mutations, we screened the poly-A tract for mutations, but no mutations were detected. Additional screening for mutations of the RII gene revealed a GG to TT base substitution in one cell line, which did not express RII. This mutation generates a stop codon resulting in predicted synthesis of a truncated RII of 219 amino acids. The nature of the mutation, which has not previously been observed in RII, has been linked to exposure to benzo[a]-pyrene, a component of cigarette smoke. Since RII has been mapped to chromosome 3p22 and nearby loci are often hypermethylated in SCLC, it was examined whether the lack of RII expression was due to hypermethylation. Southern blot analysis of the RII promoter did not show altered methylation patterns. The restriction endonuclease pattern of the RII gene was altered in two SCLC cell lines when digested with Smal. However, treatment with 5-aza-2'-deoxycytidine did not induce expression of RII mRNA. Our results indicate that in SCLC lack of RII mRNA is not commonly due to mutations and inactivation of RII transcription was not due to hypermethylation of the RII promoter or gene. Thus, these data show that in most cases of the SCLC cell lines, the RII gene and promoter is intact in spite of absent RII expression. However, the nature of the mutation found could suggest that it was caused by cigarette smoking.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10098728      PMCID: PMC2362261          DOI: 10.1038/sj.bjc.6690161

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  32 in total

1.  Mammary tumor suppression by transforming growth factor beta 1 transgene expression.

Authors:  D F Pierce; A E Gorska; A Chytil; K S Meise; D L Page; R J Coffey; H L Moses
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-09       Impact factor: 11.205

2.  Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing.

Authors:  M Gonzalez-Zulueta; C M Bender; A S Yang; T Nguyen; R W Beart; J M Van Tornout; P A Jones
Journal:  Cancer Res       Date:  1995-10-15       Impact factor: 12.701

3.  Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability.

Authors:  S Markowitz; J Wang; L Myeroff; R Parsons; L Sun; J Lutterbaugh; R S Fan; E Zborowska; K W Kinzler; B Vogelstein
Journal:  Science       Date:  1995-06-02       Impact factor: 47.728

4.  Growth inhibition by transforming growth factor beta (TGF-beta) type I is restored in TGF-beta-resistant hepatoma cells after expression of TGF-beta receptor type II cDNA.

Authors:  M Inagaki; A Moustakas; H Y Lin; H F Lodish; B I Carr
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

5.  E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas.

Authors:  J R Graff; J G Herman; R G Lapidus; H Chopra; R Xu; D F Jarrard; W B Isaacs; P M Pitha; N E Davidson; S B Baylin
Journal:  Cancer Res       Date:  1995-11-15       Impact factor: 12.701

6.  Missense mutations of the transforming growth factor beta type II receptor in human head and neck squamous carcinoma cells.

Authors:  L Garrigue-Antar; T Muñoz-Antonia; S J Antonia; J Gesmonde; V F Vellucci; M Reiss
Journal:  Cancer Res       Date:  1995-09-15       Impact factor: 12.701

7.  Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression.

Authors:  A T Ferguson; R G Lapidus; S B Baylin; N E Davidson
Journal:  Cancer Res       Date:  1995-06-01       Impact factor: 12.701

8.  Lack of transforming growth factor-beta 1 expression in benign skin tumors of p53null mice is prognostic for a high risk of malignant conversion.

Authors:  W Cui; C J Kemp; E Duffie; A Balmain; R J Akhurst
Journal:  Cancer Res       Date:  1994-11-15       Impact factor: 12.701

9.  Mutations of the transforming growth factor-beta type II receptor gene and genomic instability in hereditary nonpolyposis colorectal cancer.

Authors:  S L Lu; Y Akiyama; H Nagasaki; K Saitoh; Y Yuasa
Journal:  Biochem Biophys Res Commun       Date:  1995-11-13       Impact factor: 3.575

10.  Growth suppression by transforming growth factor beta 1 of human small-cell lung cancer cell lines is associated with expression of the type II receptor.

Authors:  P Nørgaard; L Damstrup; K Rygaard; M Spang-Thomsen; H Skovgaard Poulsen
Journal:  Br J Cancer       Date:  1994-05       Impact factor: 7.640

View more
  26 in total

Review 1.  EGFR/TGFα and TGFβ/CTGF Signaling in Neuroendocrine Neoplasia: Theoretical Therapeutic Targets.

Authors:  M Kidd; S Schimmack; B Lawrence; D Alaimo; I M Modlin
Journal:  Neuroendocrinology       Date:  2012-06-15       Impact factor: 4.914

2.  Induction of lung epithelial cell transformation and fibroblast activation by Yunnan tin mine dust and their interaction.

Authors:  Li Bian; Yong-Wen He; Rui-Zhu Tang; Li-Ju Ma; Chun-Yan Wang; Yong-Hua Ruan; Qian Gao; Ke-Wei Jin
Journal:  Med Oncol       Date:  2010-08-18       Impact factor: 3.064

3.  Establishment and characterization of six human lung cancer cell lines: EGFR, p53 gene mutations and expressions of drug sensitivity genes.

Authors:  Ja-Lok Ku; Kyung-Hee Kim; Jin-Sung Choi; You-Kyung Jeon; Sung-Hee Kim; Young-Kyoung Shin; Tae-You Kim; Yung-Jue Bang; Woo Ho Kim; Jae-Gahb Park
Journal:  Cell Oncol (Dordr)       Date:  2011-02-02       Impact factor: 6.730

4.  Elucidating the mechanism of regulation of transforming growth factor β Type II receptor expression in human lung cancer cell lines.

Authors:  Sunil K Halder; Yong-Jig Cho; Arunima Datta; Govindaraj Anumanthan; Amy-Joan L Ham; David P Carbone; Pran K Datta
Journal:  Neoplasia       Date:  2011-10       Impact factor: 5.715

5.  Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II.

Authors:  Eyal Kalo; Yosef Buganim; Keren E Shapira; Hilla Besserglick; Naomi Goldfinger; Lilach Weisz; Perry Stambolsky; Yoav I Henis; Varda Rotter
Journal:  Mol Cell Biol       Date:  2007-09-17       Impact factor: 4.272

6.  Expression of transforming growth factor betas and their signaling receptors in stone-containing intrahepatic bile ducts and cholangiocarcinoma.

Authors:  King-Teh Lee; Tsan-Shium Liu
Journal:  World J Surg       Date:  2003-08-18       Impact factor: 3.352

7.  Genome-wide impact of the BRG1 SWI/SNF chromatin remodeler on the transforming growth factor beta transcriptional program.

Authors:  Qiaoran Xi; Wei He; Xiang H-F Zhang; Hong-Van Le; Joan Massagué
Journal:  J Biol Chem       Date:  2007-11-14       Impact factor: 5.157

8.  Class II transactivator (CIITA) deficiency in tumor cells: complicated mechanisms or not?

Authors:  Peter J van den Elsen; Nienke van der Stoep
Journal:  Am J Pathol       Date:  2003-07       Impact factor: 4.307

9.  Inhibition of transforming growth factor-beta signaling in normal lung epithelial cells confers resistance to ionizing radiation.

Authors:  Anna Reeves; Marianna Zagurovskaya; Seema Gupta; Mohammed M Shareef; Mohammed Mohiuddin; Mansoor M Ahmed
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-05-01       Impact factor: 7.038

10.  Identification of novel Smad2 and Smad3 associated proteins in response to TGF-beta1.

Authors:  Kimberly A Brown; Amy-Joan L Ham; Cara N Clark; Nahum Meller; Brian K Law; Anna Chytil; Nikki Cheng; Jennifer A Pietenpol; Harold L Moses
Journal:  J Cell Biochem       Date:  2008-10-01       Impact factor: 4.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.